Impact of Biomarkers on Personalized Medicine.
The field of personalized medicine that involves the use of measuring biomarkers in clinical samples is an area of high interest and one that has tremendous impact on drug development. With the emergence of more sensitive and specific technologies that are now able to be run in clinical settings and the ability to accurately measure biomarkers, there is a need to understand how biomarkers are defined, how they are used in clinical trials, and most importantly how they are used in conjunction with drug treatment. Biomarker approaches have entered into early clinical trials and are increasingly being used to develop new diagnostics that help to differentiate or stratify the likely outcomes of therapeutic intervention. Tremendous efforts have been made to date to discover novel biomarkers for use in clinical practice. Still, the number of markers that make it into clinical practice is rather low. In the next following chapters, we will explain the various classifications of biomarkers, how they are applied, measured, and used in personalized medicine specifically focusing on how they are used in de-risking the 10 plus years drug development process and lastly how they are validated and transformed into companion diagnostic assays.
Bayer Pharma AG, 42096, Wuppertal, Germany.
Patricia
P
Carrigan
Bayer Pharma AG, 42096, Wuppertal, Germany. thomas.krahn@bayer.com.
Thomas
T
Krahn
D015415:Biomarkers; D055808:Drug Discovery; D006801:Humans; D035683:MicroRNAs / Q000032:analysis; D057285:Precision Medicine
D015415:Biomarkers; D035683:MicroRNAs
Biomarker; Biomarker classification; Biomarker technologies; Clinical trial; Companion diagnostics (CDx); Drug development; Patient stratification; Personalized medicine; Personalized treatment; Predictive biomarker; Prognostic biomarker